Q2 2026

Filed Aug 6, 2026 · 10-Q · 37 days after period end · 0001501697-26-000068

Q2 2026 · 10-Q

Revenue

$8.81M

+346.3% vs Q2 2025

Net Income

-$16.16M

N/M vs Q2 2025

EPS Diluted

-$0.13

N/M vs Q2 2025

Operating Income-$16,391,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2026	Q2 2025	Q2 2024	Q2 2023
Revenue	$8.81M	$1.97M	$563.00K	$0.00
Net Income	-$16.16M	-$25.74M	$90.83M	-$55.71M
EPS Diluted	-$0.13	-$3.47	$13.57	-$0.33

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

X4 Pharmaceuticals, Inc · CIK 1501697 · Engraved from SEC EDGAR